Researchers at Case Western Reserve University conducted a study to investigate whether a class of medications used to treat type 2 diabetes (glucagon-like peptide-1 receptor agonists (GLP-1 RAs) could reduce the risk of colorectal cancer (CRC).
The study aimed to compare the incidence of CRC in diabetes patients treated with GLP-1 RAs to those treated with other anti-diabetic agents, such as insulin or Metformin.
The study found that patients treated with GLP-1 RAs significantly reduced the incidence of colorectal cancer compared to those treated with insulin or Metformin.
Compared to insulin-treated patients, those treated with GLP-1 RAs experienced a 44% reduction in CRC incidence.
Compared with Metformin-treated patients, those on GLP-1 RAs had a 25% reduction in CRC incidence.
The results suggest that GLP-1 RAs may be more effective than other anti-diabetic drugs, such as insulin or Metformin, in reducing the risk of CRC in diabetes patients.
The study was based on a population of over 1.2 million patients with diabetes, using electronic health records for analysis. This approach allowed for comparing the effects of different anti-diabetic agents on CRC risk.
Colorectal cancer is a significant health concern, particularly for individuals with diabetes and those who are overweight or obese.
The study’s findings suggest that GLP-1 RAs, commonly used to treat type 2 diabetes, may have an additional benefit of reducing the risk of CRC. Further research and clinical trials are needed to confirm these findings and explore the potential mechanisms underlying this protective effect.
If you care about diabetes, please read studies about new way to achieve type 2 diabetes remission, and one avocado a day keeps diabetes at bay.
For more information about diabetes, please see recent studies about 5 dangerous signs you have diabetes-related eye disease, and results showing why pomegranate is super fruit for people with diabetes.
The research findings can be found in JAMA Oncology.
Copyright © 2023 Knowridge Science Report. All rights reserved.
